HR727-119

Introduced

To amend title IV of the Public Health Service Act to prohibit sale or transactions relating to human fetal tissue.

119th Congress Introduced Jan 24, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This bill closes loopholes in existing federal law that prohibits the sale of human fetal tissue. It expands the definition of "valuable consideration" (compensation) to include not just direct cash payments, but also indirect financial benefits like waived fees, forgiven debts, delayed payments, and any payments for transporting, processing, or storing fetal tissue.

Who Benefits and How

Pro-life advocacy groups and anti-abortion organizations benefit by tightening restrictions on fetal tissue transactions. The bill makes it harder for any organization to profit from fetal tissue in any way, aligning with their policy goals of limiting abortion-related activities.

Who Bears the Burden and How

Medical research institutions and universities conducting fetal tissue research face stricter rules on how they can obtain tissue samples, increasing compliance costs and potentially limiting research capabilities. Tissue processing laboratories, storage facilities, and transportation companies can no longer receive any payments for handling fetal tissue, eliminating a revenue stream. Abortion providers cannot receive compensation for fetal tissue donations, including reimbursement for processing or handling costs.

Key Provisions

  • Expands "valuable consideration" to include gifts, honoraria, and any recognition of value bestowed
  • Prohibits waiving, forgiving, reducing, or delaying fees related to fetal tissue
  • Bans all payments for transportation, implantation, processing, preservation, quality control, or storage of fetal tissue
  • Prohibits transferring items or providing services for free when a charge would customarily be made
  • Makes it illegal to forgive loans or debts in exchange for fetal tissue

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.

At a Glance

What This Bill Does

Expands the definition of 'valuable consideration' to close loopholes in the prohibition on sale of human fetal tissue

Who Benefits

  • Pro-life advocacy groups
  • Anti-abortion organizations

Who Bears Costs

  • Medical research institutions
  • Universities conducting fetal tissue research
  • Tissue processing laboratories

Key Policy Areas

Healthcare, Medical Research, Reproductive Health

Primary Purpose

Expands the definition of 'valuable consideration' to close loopholes in the prohibition on sale of human fetal tissue

Policy Domains

Healthcare Medical Research Reproductive Health

Legislative Strategy

"Tighten restrictions on fetal tissue transactions by broadening what constitutes prohibited 'valuable consideration' to include indirect financial benefits"

Identified Gains

  • Pro-life advocacy groups
  • Anti-abortion organizations

Identified Costs

  • Medical research institutions
  • Universities conducting fetal tissue research
  • Tissue processing laboratories
  • Abortion providers
  • Transportation and storage companies handling fetal tissue

Legislative Progress

Introduced
Introduced Committee Passed
Jan 24, 2025

Mr. Scott Franklin of Florida (for himself, Mr. Weber of …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Research & Science
1 mention across 1 clause
-1 negative

Medical research institutions using human fetal tissue

Medical Laboratories
1 mention across 1 clause
-1 negative

Tissue processing and storage laboratories

Healthcare
1 mention across 1 clause
-1 negative

Abortion providers and clinics

Transportation
1 mention across 1 clause
-1 negative

Transportation companies handling medical specimens

Education
1 mention across 1 clause
-1 negative

Universities conducting fetal tissue research

1/2
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Medical Research
Actor Mappings
"the_secretary"
→ Secretary of Health and Human Services

Key Definitions

Terms defined in this bill

1 term
"valuable consideration" §2

Expanded to include: (A) any payment made or debt incurred; (B) any gift, honorarium, or recognition of value bestowed; (C) any price, charge, or fee which is waived, forgiven, reduced, or indefinitely delayed; (D) any loan or debt which is canceled or otherwise forgiven; (E) the transfer of any item from one person to another or provision of any service or granting of any opportunity for which a charge is customarily made, without charge or for a reduced charge; and (F) any payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology